Fungal eye infections may seem rare—but when they strike, the results can be devastating. Millions across the globe are affected, with South and Southeast Asia seeing especially high numbers. Despite the threat it poses, fungal endophthalmitis still lacks unified diagnostic and treatment standards. Why? It’s largely due to its low occurrence compared to bacterial infections, inconsistent clinical symptoms, and the scarcity of large-scale research. The result is alarming: patients are often misdiagnosed, treatment is delayed, and irreversible blindness becomes a tragic consequence. And this is where things get controversial—rising antifungal resistance and the lack of standardized testing are making clinical management more difficult than ever before.
Recognizing this urgent need, a major research collaboration led by the Asia-Pacific Vitreo-Retina Society (APVRS), the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII) united experts across 12 countries to take on the challenge. Their work, published in Eye and Vision (DOI: 10.1186/s40662-025-00456-y) in October 2025, delivers 20 evidence-based consensus statements—the first comprehensive regional guidelines dedicated to this life-altering infection. This collaborative document harmonizes diverse clinical viewpoints on early diagnosis, antifungal strategies, surgical interventions like vitrectomy, and even the heated debate over corticosteroids.
The project, coordinated by Professors Taraprasad Das and Dennis S. C. Lam, distilled decades of collective expertise into five key areas: disease definition, clinical recognition, biological mechanisms, treatment approaches, and future directions. Among the most critical agreements were that fungal infections tend to develop later than bacterial ones; Aspergillus, Candida, and Fusarium are the main culprits; and that those with weakened immune systems face the highest risk. Early vitrectomy—a surgical removal of the eye’s vitreous gel—was strongly encouraged to reduce fungal buildup and improve drug delivery. The experts also emphasized a combined use of intravitreal, systemic, and topical antifungal medications for best results.
Molecular techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and MALDI-TOF were recognized as game-changers, especially for culture-negative or hard-to-identify cases. But here’s where opinions split: only one in four experts supported the use of intravitreal corticosteroids (such as dexamethasone), warning that immune suppression could worsen the infection. This controversy continues to divide clinicians—are steroids ever worth the risk?
Looking forward, the team calls for stronger antifungal stewardship and faster diagnostic tools, including biomarkers like 1,3 β-D-glucan and galactomannan. They also spotlight promising next-generation antifungal drugs, notably olorofim and terbinafine, for tackling resistant strains. These additions could reshape how ophthalmologists respond to fungal threats in the near future.
Fungal endophthalmitis often flies under the radar, but when it does occur, the outcome can be catastrophic. By pooling regional experience and data, this initiative bridges the persistent gap between theory and real-world practice. The resulting framework gives eye specialists a structured path from diagnosis to recovery, prioritizing fast action and precise antifungal use to preserve what matters most—vision.
This new consensus isn’t just a guideline—it’s a milestone for ophthalmology. For clinicians in resource-limited areas, it offers a lifeline: clear diagnostic criteria, defined treatment strategies, and a new commitment to early detection. Broader adoption of molecular diagnostics and stewardship programs will also slow resistance and strengthen global preparedness. More profoundly, the document underscores an urgent global priority—coordinated surveillance and research on new pathogens like Candida auris. Together, these recommendations lay the groundwork for multicenter trials, stronger evidence-based care, and better patient outcomes worldwide.
But what do you think? Should the cautious use of corticosteroids still have a role in fungal endophthalmitis treatment, or does the risk outweigh the reward? Share your thoughts—this debate is far from over.
